9 Rue du 4 Septembre
About LimFlow SALimFlow was founded by the European medical device accelerator MD Start in 2012 and has developed the world’s first system for creating a percutaneous Deep Vein Arterialization of the foot for the treatment of End Stage Critical Limb Ischemia. This is the first ever successfully-completed fully-endovascular approach to achieving venous arterialization of the leg.
Founder and CTO: Tim Lenihan
CEO: Dan Rose
14 articles with LimFlow SA
CORRECTING and REPLACING First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-threatening Ischemia
LimFlow SA announced that the first patient has been treated in its PROMISE II U.S. pivotal trial of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-threatening Ischemia
Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options
LimFlow Announces Positive Six-Month Data From Promise I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-Option Patient Population
LimFlow SA announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the LimFlow Percutaneous Deep Vein Arterialization System.
LimFlow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
PROMISE II is a multi-center, prospective, single-arm study to be conducted in the U.S. and Japan.
The company appointed Zachary Woodson as VP of regulatory affairs and quality, and Theo Mastrokostopoulos as VP of sales and market development.
LimFlow Completes Enrollment In U.S. Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System
LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), today announced completion of enrollment of the original 10-patient cohort in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
LimFlow Announces Publication Of Positive Results From Pilot Study Of Limflow Percutaneous Deep Vein Arterialization (pDVA) System
LimFlow Announces First Patient Treated In U.S. Feasibility Study And Commencement Of International Post-Market Study
LimFlow Receives FDA Approval For U.S. Feasibility Study Of Minimally-Invasive Technology Designed To Restore Perfusion In "No Option" Critical Limb Ischemia Patients
LimFlow Receives CE Mark For Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed To Restore Perfusion For “No Option” Patients